Post Hoc Efficacy Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Post hoc efficacy analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Post Hoc Efficacy Analysis Today - Breaking & Trending Today

Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR)


Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR)
Presentation of Phase 1/2 LIBRETTO-001 trial data will highlight safety and efficacy data of Retevmo® (selpercatinib) in the treatment of RET fusion-positive cancers outside of lung and thyroid cancer
Preclinical characterization data will be presented for oral SERD, BCL2 inhibitor, next-generation KRAS-G12C, and RET inhibitors
News provided by
Share this article
Share this article
INDIANAPOLIS, March 10, 2021 /PRNewswire/  Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, to be held virtually April 10-15, 2021. During the meeting, Lilly Oncology will present data from a study exploring safety and efficacy of its selective RET-kinase inhibitor Retevmo ....

United States , Informationfor Retevmo , Lauren Cohen , Carole Copeland , Kevin Hern , Eli Lilly , Drug Administration , Lilly United States , Clinical Research Excluding Trials , Exchange Commission , Lilly Research Laboratories , American Association For Cancer Research , Oriented Innovative Clinical Research , Cancer Research , Annual Meeting , Lilly Oncology , Loxo Oncology , Accelerated Approval , Investigational New Drug Application , Targeted Therapy , Ovarian Cancer Trials , Clinical Trials Plenary , Post Hoc Efficacy Analysis , Clinical Research , Excluding Trials , Disease Oriented Innovative Clinical Research ,